How to search?
advanced search

Search results

Filters

  • Journals
  • Authors
  • Keywords
  • Date
  • Type

Search results

Number of results: 3
items per page: 25 50 75
Sort by:

Prognostic role of clinical presentation, cytological picture and response to treatment in canine centroblastic lymphoma

K. Kliczkowska-Klarowicz D. Jagielski M. Czopowicz R. Sapierzyński
Polish Journal of Veterinary Sciences | 2021 | vol. 24 | No 1 | 101-107 | DOI: 10.24425/pjvs.2021.136798
Keywords lymphoma prognostic factors chemotherapy asparaginase mitoxantron
Download PDF Download RIS Download Bibtex

Abstract

Centroblastic lymphoma (CBL) is the most common type of lymphoma in dogs and it usually responds well to chemotherapy. The aim of the study was to provide useful prognostic factors for dogs with CBL. Data regarding sex, breed, age, signalment, treatment and clinical course of the disease from 52 dogs diagnosed with centroblastic lymphoma (CBL) with cytology and immunocytochemistry were provisionally collected and related to the treatment outcome and survival. More than 80% of dogs were treated with chemotherapy and achieved complete remission in 80% of cases. Among the prognostic factors positively related to the overall survival time of dogs with CBL were: the application of chemotherapy, achieving a complete remission, application of at least one additional chemotherapeutic agent to the basic protocol, especially the administration of mitoxantrone and asparaginase. Moreover, mitotic count 14 or higher measured in cytological slides in the area of 2,37 mm2 have been linked to shorter overall survival in dogs with CBL.
Go to article

Authors and Affiliations

K. Kliczkowska-Klarowicz
1
D. Jagielski
2
M. Czopowicz
3
R. Sapierzyński
1
  1. Division of Pathology, Department of Pathology and Veterinary Diagnostics, Institute of Veterinary Medicine, Warsaw University of Life Sciences (SGGW), Nowoursynowska 159c, 02-776 Warsaw
  2. Białobrzeska Veterinary Surgery in Warsaw, Poland
  3. Division of Veterinary Epidemiology and Economics, Institute of Veterinary Medicine, Warsaw University of Life Sciences (SGGW), Nowoursynowska 159c, 02-776 Warsaw, Poland

Immunohistochemical assessment of metalloproteinases MMP2 and MMP9 expression in canine various subtypes of lymphomas in relation with proliferative and apoptotic markers

J. Sokołowska K. Urbańska
Polish Journal of Veterinary Sciences | 2019 | vol.22 | No 2 | 203–211 | DOI: 10.24425/pjvs.2019.127087
Keywords apoptotic markers dog immunolabelling lymphoma matrix metalloproteinases proliferative markers
Download PDF Download RIS Download Bibtex

Abstract

Matrix metalloproteinases 2 and 9 (MMP2 and MMP9) are proteolytic enzymes involved with extracellular matrix degradation. They play a role in tumor invasion and metastases. Be- cause of their ability to degrade signaling molecules presented in extracellular matrix, MMPs contribute to tumor proliferation and apoptosis. The aim of this study was to evaluate expression of MMP2 (latent and both active and latent forms) and MMP9 (active, latent, active and latent forms) in different subtypes of canine lymphomas and their relationship with proliferative (mi- totic index and percentage of Ki67-positive cells) and apoptotic (apoptotic index) markers. Ex- pression of MMPs was assessed immunohistochemically using an immunoreactive score system. Expression of both MMPs was found in all 20 examined lymphomas belonging to six subtypes. Most cases showed a moderate level of all analyzed forms of MMP2 and MMP9. High expres- sion of MMPs was found in single cases. Except for a positive correlation between the active form of MMP9 and the mitotic index for all lymphoma cases, no other correlations between any remaining forms of MMPs and neither proliferative nor apoptotic markers were found, irrespec- tive of whether the analysis encompassed all cases or the most numerous lymphoma subtypes i.e. centroblastic and Burkitt-like. Our results were not able to clearly confirm the influence of MMPs on the proliferation and apoptotic activity of canine lymphoma cells. However, further studies examining MMPs activity by zymography, expression of their inhibitors and other factors in- volved in activation of cell proliferation and apoptosis inhibition are needed to clarify the role of MMPs, especially the active form of MMP9, in the behavior of canine lymphoma cells.

Go to article

Authors and Affiliations

J. Sokołowska
K. Urbańska

Outcomes of Jehovah’s Witnesses with hematological malignancies treated without transfusions — single center experience

Joanna Ewa Drozd-Sokołowska Anna Waszczuk-Gajda Jadwiga Dwilewicz-Trojaczek Alicja Walesiak Monika Krzyżanowska Monika Paluszewska Jolanta Wieczorek Wiesław Wiktor-Jędrzejczak
Folia Medica Cracoviensia | 2020 | Vol. 60 | No 4 | 53-64 | DOI: 10.24425/fmc.2020.136204
Keywords Jehovah’s Witnesses leukemia lymphoma blood transfusion platelet transfusion
Download PDF Download RIS Download Bibtex

Abstract

Malignancies of the hematopoietic system frequently are associated with severe cytopenias requiring transfusions of blood components. Refusal of blood components by Jehovah’s Witnesses (JW) produces challenges to treatment. In this report we describe the outcome of hematological malignancies of JW patients treated without transfusions. Altogether, eight JW, diagnosed 1994–2015, 6 (75%) females, the median age at diagnosis 40 years (range, 20–78), were included into the analysis. The diagnoses were: acute lymphoblastic leukemia (2, 25%), acute myeloid leukemia (2, 25%), non-Hodgkin’s lymphomas (4, 50%). One patient died without treatment while the remaining 7 patients received treatment, including imatinib in 1 patient with BCR-ABL1+ acute lymphoblastic leukemia. Five (62.5%) patients received erythropoiesis stimulating agents. Median hemoglobin concentration at diagnosis was 8.7 g/dL (range, 6.3–13.1), and it decreased to 3.2 g/dL (range, 2.6–9.3) during first-line treatment. Median platelet count at diagnosis was 52 × 109/L (range, 15–392). All patients became thrombocytopenic upon treatment reaching median platelet count 8 × 109/L (range, 2–85). Five patients developed respiratory failure. Anemia contributed substantially to the death of 3 out of 6 patients (50%). One patient (17%) developed central nervous system bleeding in the course of thrombocytopenia. Objective response rate was 43%, with 29% complete remissions after first-line treatment. Despite the median overall survival of 15.3 months (95% CI, 0.2–52.2), all but one acute leukemia patients succumbed shortly after the diagnosis. To conclude, the outcome of JW treated because of hematological malignancies without blood transfusions is very dismal, nevertheless, selected patients can obtain complete remissions. Anemia contributes significantly to the death of JW.
Go to article

Bibliography

1. Bouchnita A., Eymard N., Moyo T.K., Koury M.J., Volpert V.: Bone marrow infiltration by multiple myeloma causes anemia by reversible disruption of erythropoiesis. Am J Hematol. 2016; 91 (4): 371– 378. doi: 10.1002/ajh.24291.
2. Wang Y., Gao A., Zhao H., et al.: Leukemia cell infiltration causes defective erythropoiesis partially through MIP-1alpha/CCL3. Leukemia. 2016; 30 (9): 1897–1908. doi: 10.1038/leu.2016.81.
3. Bohlius J., Bohlke K., Castelli R., et al.: Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. J Clin Oncol. 2019; 37 (15): 1336–1351. doi: 10.1200/JCO.18.02142.
4. Schiffer C.A., Bohlke K., Delaney M., et al.: Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2018; 36 (3): 283–299. doi: 10.1200/JCO.2017.76.1734.
5. Drozd-Sokolowska J.E., Wiktor-Jedrzejczak W.: Factors determining the risk of severe (WHO grades 3 and 4) hemorrhage in hematologic patients. Transfus Apher Sci. 2011; 44: 129–134. doi: 10.1016/j. transci.2011.01.004.
6. Rodgers G.M., Gilreath J.A., Alwan L., et al.: Cancer- and Chemotherapy Induced Anemia. NCCN Clinical Practice Guidelines in Oncology. https://www.nccn.org/professionals/physician_gls/f_guidelines. asp#anemia: NCCN; 2016.
7. Laszlo D., Agazzi A., Goldhirsch A., et al.: Tailored therapy of adult acute leukaemia in Jehovah’s Witnesses: unjustified reluctance to treat. Eur J Haematol. 2004; 72 (4): 264–267. doi: 10.1111/ j.0902-4441.2003.00211.x.
8. Chojnowski K., Janus A., Blizniewska K., Robak M., Trelinski J.: Long-lasting extreme anemia during the therapy of acute lymphoblastic leukemia in a Jehovah’s Witness patient. Transfusion. 2016; 56 (10): 2438–2442. doi: 10.1111/trf.13703.
9. Mazza P., Palazzo G., Amurri B., Cervellera M., Rizzo C., Maggi A.: Acute leukemia in Jehovah’s Witnesses: a challenge for hematologists. Haematologica. 2000; 85: 1221–1222.
10. Brown N.M., Keck G., Ford P.A.: Acute myeloid leukemia in Jehovah Witnesses. Leuk Lymphoma. 2008; 49 (4): 817–820. doi: 10.1080/10428190801911670.
11. Cullis J.O., Duncombe A.S., Dudley J.M., Lumley H.S., Apperley J.F., Smith A.G.: Acute leukaemia in Jehovah’s Witnesses. Br J Haematol. 1998; 100 (4): 664–668. doi: 10.1046/j.1365-2141.1998.00634.x.
12. Wilop S., Osieka R.: Antineoplastic chemotherapy in Jehovah’s Witness patients with acute myelogenous leukemia refusing blood products — a matched pair analysis. Hematology. 2018; 23 (6): 324–329. doi: 10.1080/10245332.2017.
13. Ford P.A., Grant S.J., Mick R., Keck G.: Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah’s Witnesses. J Clin Oncol. 2015; 33 (15): 1674–1679. doi: 10.1200/JCO.2014.57.9912.
14. Agapidou A., Vakalopoulou S., Papadopoulou T., Chadjiaggelidou C., Garypidou V.: Successful Treatment of Severe Anemia using Erythropoietin in a Jehovah Witness with Non-Hodgkin Lymphoma. Hematol Rep. 2014; 6 (4): 5600. doi: 10.4081/hr.2014.5600.
15. Yamamoto Y., Kawashima A., Kashiwagi E., Ogata K.: A Jehovah’s Witness with Acute Myeloid Leukemia Successfully Treated with an Epigenetic Drug, Azacitidine: A Clue for Development of Anti-AML Therapy Requiring Minimum Blood Transfusions. Case Rep Hematol. 2014; 2014: 141260. doi: 10.1155/2014/141260.
16. Garelius H., Grund S., Stockelberg D.: Induction with azacytidine followed by allogeneic hematopoietic stem cell transplantation in a Jehovah’s Witness with acute monocytic leukemia. Clin Case Rep. 2015; 3 (5): 287–290. doi: 10.1002/ccr3.212.
17. Bareford D., Odeh B., Narayanan S., Wiltshire S.: Remission induction in a Jehovah’s witness patient with acute myeloid leukaemia using gemtuzumab ozogamicin. Transfus Med. 2005; 15 (5): 445–448. doi: 10.1111/j.1365-3148.2005.00611.x.
18. Fujisawa S., Naito K., Matsuoka T., Kobayashi M.: Complete remission induced by gemtuzumab ozogamicin in a Jehovah’s Witness patient with acute myelogenous leukemia. Int J Hematol. 2007; 85 (5): 418–420. doi: 10.1532/IJH97.07018.
19. Donahue L.L., Shapira I., Shander A., Kolitz J., Allen S., Greenburg G.: Management of acute anemia in a Jehovah’s Witness patient with acute lymphoblastic leukemia with polymerized bovine hemoglobin- based oxygen carrier: a case report and review of literature. Transfusion. 2010; 50 (7): 1561– 1567. doi: 10.1111/j.1537-2995.2010.02603.x.
Go to article

Authors and Affiliations

Joanna Ewa Drozd-Sokołowska
1
Anna Waszczuk-Gajda
1
Jadwiga Dwilewicz-Trojaczek
1
Alicja Walesiak
1
Monika Krzyżanowska
1
Monika Paluszewska
1
Jolanta Wieczorek
1
Wiesław Wiktor-Jędrzejczak
1
  1. Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Poland

This page uses 'cookies'. Learn more